Pretreatment prostate specific antigen doubling times: Use in patients before radical prostatectomy

Journal of Urology

Volumn 158, Issue 5, 1997, Pages 1876-1879

  Goluboff, Erik T ^a   Heitjan, Daniel F ^a   DeVries, Glen M ^a   Katz, Aaron E ^a   Benson, Mitchell C ^a   Olsson, Carl A ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM;

EID: 0030843379     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64154-5     Document Type: Article

References (9)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics 1996: CA, 46: 5, 1996.
2. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. W.: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J.A.M.A., 270: 948, 1993.
3. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum prostate-specific antigen after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
4. Katz, A. E., de Vries, G. M., Benson, M. C., Buttyan, R. E., O'Toole, K., Rubin, M. A., Stifelman, M. and Olsson, C. A.: The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Urol. Clin. N. Amer., 23: 541, 1996.
5. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110, 1993.
6. Seaman, E. K., Whang, I. S., Cooner, W., Olsson, C. A. and Benson, M. C.: Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate. Urology, 43: 645, 1994.
7. Lee, W. R., Hanks, G. E., Corn, B. W. and Schultheiss, T. E.: Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int. J. Rad. Oncol. Biol. Phys., 31: 21, 1995.
8. Hanks, G. E., Hanlon, A. L., Lee, W. R., Slivjak, A. and Schultheiss, T. E.: Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int. J. Rad. Oncol. Biol. Phys., 34: 549, 1996.
9. Zietman, A. L., Shipley, W. U. and Coen, J. J.: Radical prostatectomy and radical radiation therapy for clinical stages T1 and 2 adenocarcinoma of the prostate. New insights into outcome from repeat biopsy and prostate-specific antigen followup. J. Urol., 152: 1806, 1994.